These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23553917)

  • 21. The pediatric preclinical testing program: description of models and early testing results.
    Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock R; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA
    Pediatr Blood Cancer; 2007 Dec; 49(7):928-40. PubMed ID: 17066459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
    Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y
    Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial testing of cisplatin by the pediatric preclinical testing program.
    Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
    Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
    Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ; Lock RB
    Pediatr Blood Cancer; 2010 Dec; 55(7):1329-37. PubMed ID: 20740623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.
    Carol H; Reynolds CP; Kang MH; Keir ST; Maris JM; Gorlick R; Kolb EA; Billups CA; Geier B; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB
    Pediatr Blood Cancer; 2013 Apr; 60(4):633-41. PubMed ID: 22753001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
    Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Lyalin D
    Pediatr Blood Cancer; 2014 Aug; 61(8):1493-6. PubMed ID: 24664981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
    Gill J; Zhang W; Zhang Z; Roth M; Harrison DJ; Rowshan S; Erickson S; Gatto G; Kurmasheva R; Houghton P; Teicher B; Smith MA; Kolb EA; Gorlick R
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28606. PubMed ID: 32706456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial testing of topotecan by the pediatric preclinical testing program.
    Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB
    Pediatr Blood Cancer; 2010 May; 54(5):707-15. PubMed ID: 20017204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
    Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
    Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
    Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Oct; 63(10):1744-52. PubMed ID: 27238606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
    Houghton PJ; Gorlick R; Kolb EA; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Phelps D; Maris JM; Billups C; Smith MA
    Pediatr Blood Cancer; 2012 Feb; 58(2):191-9. PubMed ID: 21337679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
    Keir ST; Maris JM; Lock R; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2010 Dec; 55(6):1126-33. PubMed ID: 20672370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
    Keir ST; Maris JM; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 May; 60(5):783-90. PubMed ID: 23335050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1190-7. PubMed ID: 18260118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial testing of lenalidomide by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Keir ST; Gorlick R; Kolb EA; Lock R; Maris JM; Carol H; Morton CL; Billups CA; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):606-11. PubMed ID: 21360651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Jul; 51(1):42-8. PubMed ID: 18293383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
    Kawano S; Asano M; Adachi Y; Matsui J
    Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
    Kang MH; Reynolds CP; Houghton PJ; Alexander D; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Maris JM; Wozniak A; Smith MA
    Pediatr Blood Cancer; 2012 Jul; 59(1):185-8. PubMed ID: 21538821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Keir ST; Maris JM; Kang MH; Reynolds CP; Lock RB; Carol H; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2015 Jun; 62(6):1106-9. PubMed ID: 25407467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.